| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 41 | 2022 | 5317 | 3.040 |
Why?
|
| Polymorphism, Single Nucleotide | 30 | 2020 | 4549 | 1.870 |
Why?
|
| C-Reactive Protein | 4 | 2017 | 527 | 1.710 |
Why?
|
| Skin Neoplasms | 29 | 2022 | 4654 | 1.640 |
Why?
|
| Genome-Wide Association Study | 24 | 2020 | 2265 | 1.510 |
Why?
|
| Genetic Predisposition to Disease | 21 | 2020 | 5539 | 1.400 |
Why?
|
| Interleukin-12 Subunit p40 | 2 | 2015 | 29 | 1.030 |
Why?
|
| Quantitative Trait Loci | 4 | 2020 | 374 | 0.750 |
Why?
|
| Biomarkers, Tumor | 9 | 2021 | 10331 | 0.740 |
Why?
|
| Chemokines | 1 | 2019 | 314 | 0.620 |
Why?
|
| Vitamin D | 2 | 2017 | 261 | 0.600 |
Why?
|
| Germ-Line Mutation | 3 | 2017 | 1046 | 0.550 |
Why?
|
| Case-Control Studies | 17 | 2020 | 6100 | 0.510 |
Why?
|
| Body Mass Index | 3 | 2018 | 2203 | 0.500 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 992 | 0.480 |
Why?
|
| Genotype | 13 | 2020 | 4109 | 0.470 |
Why?
|
| Social Class | 5 | 2008 | 310 | 0.430 |
Why?
|
| Genetic Variation | 7 | 2018 | 2086 | 0.420 |
Why?
|
| Risk Assessment | 7 | 2018 | 6869 | 0.410 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 1586 | 0.410 |
Why?
|
| Psoriasis | 1 | 2011 | 126 | 0.360 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2011 | 158 | 0.360 |
Why?
|
| Cytokines | 1 | 2019 | 2809 | 0.360 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2010 | 185 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2010 | 179 | 0.350 |
Why?
|
| Multivariate Analysis | 8 | 2016 | 4298 | 0.340 |
Why?
|
| Inflammation | 1 | 2019 | 2522 | 0.340 |
Why?
|
| Female | 53 | 2023 | 141928 | 0.320 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2011 | 3552 | 0.320 |
Why?
|
| Computational Biology | 2 | 2014 | 1271 | 0.320 |
Why?
|
| Male | 45 | 2022 | 123000 | 0.320 |
Why?
|
| Humans | 71 | 2024 | 261506 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 507 | 0.290 |
Why?
|
| Telomere Homeostasis | 2 | 2017 | 73 | 0.290 |
Why?
|
| Nuclear Proteins | 3 | 2015 | 3343 | 0.280 |
Why?
|
| Epistasis, Genetic | 3 | 2016 | 119 | 0.280 |
Why?
|
| Aged | 39 | 2022 | 70117 | 0.280 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 2005 | 38 | 0.280 |
Why?
|
| Aged, 80 and over | 30 | 2019 | 29902 | 0.270 |
Why?
|
| DNA, Neoplasm | 3 | 2017 | 1910 | 0.270 |
Why?
|
| Cohort Studies | 12 | 2019 | 9244 | 0.260 |
Why?
|
| Proportional Hazards Models | 9 | 2018 | 4988 | 0.260 |
Why?
|
| Middle Aged | 29 | 2019 | 86204 | 0.260 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 2488 | 0.260 |
Why?
|
| Prognosis | 15 | 2021 | 21713 | 0.250 |
Why?
|
| Melphalan | 1 | 2007 | 834 | 0.250 |
Why?
|
| Genetic Loci | 4 | 2020 | 481 | 0.250 |
Why?
|
| Leukocytes | 2 | 2017 | 422 | 0.240 |
Why?
|
| DNA, Mitochondrial | 2 | 2016 | 311 | 0.240 |
Why?
|
| Breast Neoplasms | 11 | 2011 | 15694 | 0.230 |
Why?
|
| Telomere | 3 | 2017 | 505 | 0.230 |
Why?
|
| Prostatectomy | 1 | 2008 | 962 | 0.230 |
Why?
|
| Survival Analysis | 6 | 2019 | 9180 | 0.230 |
Why?
|
| Risk Factors | 18 | 2018 | 17523 | 0.220 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2007 | 519 | 0.220 |
Why?
|
| Neoplasm Staging | 12 | 2019 | 13658 | 0.220 |
Why?
|
| SEER Program | 11 | 2011 | 1000 | 0.210 |
Why?
|
| DNA-Binding Proteins | 4 | 2016 | 4821 | 0.210 |
Why?
|
| United States | 15 | 2017 | 15433 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2019 | 6207 | 0.190 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2019 | 12 | 0.170 |
Why?
|
| Adult | 19 | 2019 | 77950 | 0.170 |
Why?
|
| MicroRNAs | 2 | 2023 | 2947 | 0.170 |
Why?
|
| Neoplasms | 4 | 2017 | 15193 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2015 | 1439 | 0.160 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2018 | 29 | 0.160 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2018 | 83 | 0.160 |
Why?
|
| Matrix Metalloproteinase 16 | 1 | 2017 | 2 | 0.160 |
Why?
|
| Tolloid-Like Metalloproteinases | 1 | 2017 | 3 | 0.160 |
Why?
|
| ADAMTS Proteins | 1 | 2017 | 15 | 0.160 |
Why?
|
| Procollagen N-Endopeptidase | 1 | 2017 | 10 | 0.160 |
Why?
|
| Alleles | 5 | 2018 | 2437 | 0.160 |
Why?
|
| RNA, Long Noncoding | 1 | 2023 | 598 | 0.160 |
Why?
|
| Polymorphism, Genetic | 2 | 2015 | 1450 | 0.150 |
Why?
|
| Heterozygote | 2 | 2011 | 1020 | 0.150 |
Why?
|
| Lung Neoplasms | 3 | 2024 | 11538 | 0.150 |
Why?
|
| Prostatic Neoplasms | 3 | 2012 | 5767 | 0.150 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2017 | 40 | 0.150 |
Why?
|
| Erythropoietin | 2 | 2011 | 205 | 0.150 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2008 | 1039 | 0.150 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 419 | 0.150 |
Why?
|
| Calcium Signaling | 1 | 2019 | 284 | 0.150 |
Why?
|
| Interleukin-6 | 1 | 2021 | 1038 | 0.150 |
Why?
|
| Age Factors | 5 | 2011 | 5377 | 0.150 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2017 | 100 | 0.150 |
Why?
|
| Gelsolin | 1 | 2016 | 14 | 0.140 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2016 | 42 | 0.140 |
Why?
|
| Mucin 5AC | 1 | 2016 | 75 | 0.140 |
Why?
|
| Receptors, Calcitriol | 1 | 2017 | 134 | 0.140 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2016 | 16 | 0.140 |
Why?
|
| Disease Progression | 4 | 2015 | 6682 | 0.140 |
Why?
|
| Base Pairing | 1 | 2016 | 68 | 0.140 |
Why?
|
| Young Adult | 11 | 2019 | 21445 | 0.140 |
Why?
|
| Obesity | 3 | 2018 | 2884 | 0.140 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2016 | 42 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2007 | 2138 | 0.140 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2017 | 360 | 0.140 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2017 | 177 | 0.140 |
Why?
|
| Endoribonucleases | 1 | 2016 | 107 | 0.140 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 10001 | 0.130 |
Why?
|
| Databases, Genetic | 2 | 2016 | 745 | 0.130 |
Why?
|
| Pigmentation | 4 | 2020 | 47 | 0.130 |
Why?
|
| Survival Rate | 12 | 2017 | 12221 | 0.130 |
Why?
|
| Antineoplastic Agents | 3 | 2007 | 14289 | 0.130 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 1 | 2015 | 47 | 0.130 |
Why?
|
| Integrins | 1 | 2016 | 262 | 0.130 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 237 | 0.130 |
Why?
|
| Fanconi Anemia Complementation Group A Protein | 1 | 2014 | 7 | 0.130 |
Why?
|
| Wnt Proteins | 1 | 2017 | 397 | 0.130 |
Why?
|
| Incidence | 3 | 2017 | 5673 | 0.130 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2015 | 99 | 0.130 |
Why?
|
| Telomere-Binding Proteins | 1 | 2015 | 85 | 0.130 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 3230 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2018 | 15862 | 0.120 |
Why?
|
| Fanconi Anemia | 1 | 2014 | 88 | 0.120 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 1341 | 0.120 |
Why?
|
| Glycoproteins | 1 | 2017 | 747 | 0.110 |
Why?
|
| Confidence Intervals | 1 | 2015 | 756 | 0.110 |
Why?
|
| Haplotypes | 2 | 2016 | 856 | 0.110 |
Why?
|
| Medicare | 5 | 2011 | 860 | 0.110 |
Why?
|
| Sequence Deletion | 1 | 2016 | 875 | 0.110 |
Why?
|
| Trans-Activators | 2 | 2016 | 1555 | 0.110 |
Why?
|
| Genes, BRCA2 | 1 | 2014 | 309 | 0.110 |
Why?
|
| Phenotype | 4 | 2020 | 6295 | 0.110 |
Why?
|
| Nevus | 1 | 2012 | 107 | 0.100 |
Why?
|
| DNA Methylation | 3 | 2017 | 2669 | 0.100 |
Why?
|
| Adolescent | 11 | 2019 | 31252 | 0.100 |
Why?
|
| Ovarian Neoplasms | 1 | 2007 | 4638 | 0.100 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 324 | 0.100 |
Why?
|
| Sunlight | 3 | 2017 | 79 | 0.100 |
Why?
|
| Muscle Proteins | 1 | 2015 | 549 | 0.100 |
Why?
|
| Lod Score | 1 | 2010 | 157 | 0.100 |
Why?
|
| Transcription Factors | 2 | 2015 | 5270 | 0.100 |
Why?
|
| Skin | 1 | 2016 | 1259 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 2216 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2015 | 1073 | 0.090 |
Why?
|
| Thromboembolism | 1 | 2011 | 155 | 0.090 |
Why?
|
| Codon | 1 | 2010 | 241 | 0.090 |
Why?
|
| Breast Neoplasms, Male | 1 | 2011 | 229 | 0.090 |
Why?
|
| Models, Genetic | 1 | 2013 | 1113 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2015 | 1152 | 0.090 |
Why?
|
| Age of Onset | 1 | 2011 | 827 | 0.080 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 14889 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 3 | 2016 | 276 | 0.080 |
Why?
|
| ROC Curve | 3 | 2018 | 1183 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.080 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 1516 | 0.080 |
Why?
|
| Health Status Disparities | 2 | 2008 | 291 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 6009 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 5159 | 0.080 |
Why?
|
| Fractures, Bone | 2 | 2008 | 291 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2012 | 4892 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 4367 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2330 | 0.080 |
Why?
|
| Signal Transduction | 4 | 2024 | 11965 | 0.080 |
Why?
|
| Treatment Refusal | 1 | 2008 | 128 | 0.080 |
Why?
|
| Datasets as Topic | 2 | 2019 | 181 | 0.070 |
Why?
|
| Diabetes Complications | 1 | 2009 | 305 | 0.070 |
Why?
|
| Skin Pigmentation | 2 | 2017 | 47 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2012 | 1171 | 0.070 |
Why?
|
| Epoetin Alfa | 1 | 2005 | 27 | 0.070 |
Why?
|
| Bone Density Conservation Agents | 1 | 2008 | 198 | 0.070 |
Why?
|
| Diphosphonates | 1 | 2008 | 262 | 0.070 |
Why?
|
| Sex Factors | 1 | 2011 | 2139 | 0.070 |
Why?
|
| Filgrastim | 1 | 2005 | 191 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 1021 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2007 | 241 | 0.060 |
Why?
|
| Hematinics | 1 | 2005 | 109 | 0.060 |
Why?
|
| Proteins | 1 | 2013 | 1963 | 0.060 |
Why?
|
| Thrombosis | 1 | 2011 | 781 | 0.060 |
Why?
|
| Genome, Human | 1 | 2012 | 1869 | 0.060 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 1 | 2023 | 36 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2011 | 2218 | 0.060 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2023 | 55 | 0.060 |
Why?
|
| Treatment Outcome | 6 | 2018 | 32848 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2009 | 3890 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2008 | 2231 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 1382 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2005 | 749 | 0.050 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 1084 | 0.050 |
Why?
|
| Stroke | 1 | 2011 | 1144 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 4971 | 0.050 |
Why?
|
| Mammography | 1 | 2008 | 1010 | 0.050 |
Why?
|
| Survivors | 1 | 2007 | 1031 | 0.050 |
Why?
|
| Genomics | 1 | 2012 | 2738 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2017 | 2316 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2016 | 12873 | 0.050 |
Why?
|
| Mice, Inbred A | 1 | 2020 | 33 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 2045 | 0.050 |
Why?
|
| CD146 Antigen | 1 | 2020 | 57 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2024 | 7226 | 0.050 |
Why?
|
| Radiotherapy | 1 | 2008 | 1824 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 2927 | 0.050 |
Why?
|
| Time Factors | 2 | 2018 | 12926 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2016 | 1546 | 0.040 |
Why?
|
| Patient Selection | 1 | 2007 | 2055 | 0.040 |
Why?
|
| Algorithms | 1 | 2011 | 3890 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2023 | 1064 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 1390 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 703 | 0.040 |
Why?
|
| Socioeconomic Factors | 3 | 2008 | 1225 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 106 | 0.040 |
Why?
|
| Biomarkers | 2 | 2021 | 5047 | 0.040 |
Why?
|
| Retrospective Studies | 5 | 2018 | 37905 | 0.040 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2016 | 39 | 0.040 |
Why?
|
| Prevalence | 3 | 2011 | 3260 | 0.040 |
Why?
|
| 5-Methylcytosine | 1 | 2017 | 56 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 14551 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2016 | 80 | 0.040 |
Why?
|
| p21-Activated Kinases | 1 | 2016 | 122 | 0.040 |
Why?
|
| Vitamin D Deficiency | 1 | 2017 | 115 | 0.030 |
Why?
|
| Cell Movement | 1 | 2023 | 2466 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2024 | 4804 | 0.030 |
Why?
|
| Registries | 3 | 2008 | 2170 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2008 | 2576 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2016 | 460 | 0.030 |
Why?
|
| Educational Status | 2 | 2007 | 397 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2022 | 1283 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2006 | 1833 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 1163 | 0.030 |
Why?
|
| Melanocytes | 1 | 2015 | 219 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2017 | 430 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2015 | 295 | 0.030 |
Why?
|
| Dioxygenases | 1 | 2014 | 159 | 0.030 |
Why?
|
| Telomerase | 1 | 2016 | 525 | 0.030 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2013 | 28 | 0.030 |
Why?
|
| China | 1 | 2014 | 606 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2020 | 4307 | 0.030 |
Why?
|
| Lymphangiogenesis | 1 | 2013 | 46 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2008 | 10035 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 677 | 0.030 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 2012 | 50 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2013 | 166 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2015 | 829 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 3821 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 1972 | 0.030 |
Why?
|
| Comorbidity | 2 | 2008 | 2352 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1217 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 313 | 0.020 |
Why?
|
| Mice | 2 | 2023 | 34495 | 0.020 |
Why?
|
| Texas | 2 | 2015 | 6311 | 0.020 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2011 | 159 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2012 | 288 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2011 | 327 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2013 | 1471 | 0.020 |
Why?
|
| Lymph Nodes | 2 | 2013 | 2967 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 2594 | 0.020 |
Why?
|
| Mutation | 2 | 2022 | 15179 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2015 | 1026 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2011 | 974 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2021 | 3341 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2007 | 6915 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2023 | 8873 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 573 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 384 | 0.020 |
Why?
|
| Animals | 2 | 2023 | 59536 | 0.020 |
Why?
|
| Geography | 1 | 2007 | 140 | 0.020 |
Why?
|
| DNA | 1 | 2015 | 2693 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 3570 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 854 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 1547 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2013 | 1415 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2007 | 8865 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 3441 | 0.020 |
Why?
|
| Smoking | 1 | 2014 | 2440 | 0.020 |
Why?
|
| Axilla | 1 | 2008 | 902 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 2195 | 0.010 |
Why?
|
| Imidazoles | 1 | 2008 | 999 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 5112 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 761 | 0.010 |
Why?
|
| Pain | 1 | 2008 | 1658 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2008 | 4844 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2007 | 2979 | 0.010 |
Why?
|